RMD Open

Real-world safety assessment of avacopan in patients with antineutrophil cytoplasmic antibody-associated vasculitis

Objective Postmarketing safety data of avacopan, the first Food and Drug Administration (FDA) approved drug in a decade for ...
RMD Open

Prevalence, incidence, mortality and causes of death in a large cohort of patients with rheumatoid arthritis: an Italian population-based study

Objective Rheumatoid arthritis (RA) is the most common form of inflammatory arthritis and primarily affects the joints. While ...
RMD Open

Effect of targeted therapies on pulmonary function in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis

Introduction Interstitial lung disease (ILD) is a serious extra-articular manifestation of rheumatoid arthritis (RA) associated with increased morbidity and mortality. The pulmonary safety of biologic ...
RMD Open

Autoantibody biomarkers and first-line therapy response in RA: findings from the CAP48 cohort

Objective A panel of antibodies against three antigens, University Hasselt (UH)-rheumatoid arthritis (RA).305, 318 and 329, has been associated with lack of response to first-line therapy in the Care ...
rmdopen.bmj

Active discopathy: a clinical reality

In the late 1980s, the description by Modic and colleagues of elementary discovertebral changes detected on MRI (Modic classification) suggested for the first time a possible correlation between ...
rmdopen.bmj

Induction of interleukin 21 receptor expression via enhanced intracellular metabolism in B cells and its relevance to the disease activity in systemic lupus erythematosus

Objective To elucidate the association between the changes in intracellular metabolism in the early stage of B cell activation and systemic lupus erythematosus (SLE) pathogenesis. Conclusion IL-21R ...
rmdopen.bmj

Elevated serum levels of interleukin-18 discriminate Still’s disease from other autoinflammatory conditions: results from the European ImmunAID cohort

Objectives Systemic autoinflammatory diseases (SAIDs) represent a set of conditions with exaggerated innate immune responses. IL-1β and IL-18 are key cytokines involved in the pathogenesis of some ...
rmdopen.bmj

Pericoronary fat attenuation and its association with atherosclerosis in rheumatoid arthritis compared with controls: a cross-sectional study

Objectives We compared mean and artery-specific pericoronary adipose tissue attenuation (PCATa) between rheumatoid arthritis (RA) patients and controls and examined whether clinical factors and ...
rmdopen.bmj

Longitudinal association of early axial spondyloarthritis status at the time of diagnosis with disease activity over time: 10-year results from the GESPIC cohort

Objective Recently, the definition for ‘early axial spondyloarthritis (axSpA)’ was developed by the Assessment of SpondyloArthritis international Society (ASAS), including ≤2 years of axial symptoms ...
rmdopen.bmj

Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases

Interstitial lung disease (ILD) associated with rheumatoid arthritis or with connective tissue diseases such as systemic sclerosis can be collectively named systemic autoimmune rheumatic ...
rmdopen.bmj

Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme

Objective Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). We report the largest integrated safety analysis of tofacitinib, as of March 2017, using ...